Press releases
- Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
- Newron Presents 2023 Financial Results and Provides 2024 Outlook
- Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Key statistics
On Thursday, Newron Pharmaceuticals SpA (NWPHF:PNK) closed at 8.52, -0.35% below its 52-week high of 8.55, set on Jan 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 8.52 |
Average volume | 0.00 |
---|---|
Shares outstanding | 18.63m |
Free float | 17.16m |
P/E (TTM) | -- |
Market cap | 124.34m CHF |
EPS (TTM) | -0.8826 CHF |
Data delayed at least 15 minutes, as of Jan 18 2024.
More ▼